Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 100 articles:
HTML format



Single Articles


    May 2021
  1. MARKEWITZ RDH, Dargvainiene J
    Mitotic and Apoptotic Figures on a Peripheral-Blood Smear.
    N Engl J Med. 2021;384:1942.
    PubMed    


  2. TIACCI E, De Carolis L, Simonetti E, Capponi M, et al
    Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
    N Engl J Med. 2021;384:1810-1823.
    PubMed     Abstract available


  3. MEJIA BURITICA L, Karduss Urueta AJ
    Pulmonary Mucormycosis.
    N Engl J Med. 2021;384:e69.
    PubMed    


    April 2021
  4. WEI AH, Dohner H, Roboz GJ
    Oral Azacitidine Maintenance for Acute Myeloid Leukemia. Reply.
    N Engl J Med. 2021;384:e51.
    PubMed    


  5. PERISSINOTTI AJ, Benitez LL, Marini BL
    Oral Azacitidine Maintenance for Acute Myeloid Leukemia.
    N Engl J Med. 2021;384:e51.
    PubMed    


    March 2021
  6. DUNCAVAGE EJ, Schroeder MC, O'Laughlin M, Wilson R, et al
    Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers.
    N Engl J Med. 2021;384:924-935.
    PubMed     Abstract available


    February 2021
  7. TERAO T, Matsue K
    Bone Marrow Necrosis in Acute Monoblastic Leukemia.
    N Engl J Med. 2021;384:650.
    PubMed    


    January 2021
  8. FOA R, Chiaretti S
    Dasatinib-Blinatumomab for Ph-Positive ALL. Reply.
    N Engl J Med. 2021;384:384.
    PubMed    


  9. KAMACHI K, Ureshino H
    Dasatinib-Blinatumomab for Ph-Positive ALL.
    N Engl J Med. 2021;384:384.
    PubMed    


  10. FARAG SS, Abu Zaid M, Schwartz JE, Thakrar TC, et al
    Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.
    N Engl J Med. 2021;384:11-19.
    PubMed     Abstract available


    December 2020
  11. WEI AH, Dohner H, Pocock C, Montesinos P, et al
    Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
    N Engl J Med. 2020;383:2526-2537.
    PubMed     Abstract available


    November 2020
  12. DINARDO CD, Wang J, Pratz KW
    Azacitidine and Venetoclax in AML. Reply.
    N Engl J Med. 2020;383:2088-2089.
    PubMed    


  13. MOORE JW, Pelcovits A, Reagan JL
    Azacitidine and Venetoclax in AML.
    N Engl J Med. 2020;383:2088.
    PubMed    


  14. LUCIJANIC M
    Azacitidine and Venetoclax in AML.
    N Engl J Med. 2020;383:2087-2088.
    PubMed    


  15. CHITIKELA S, Kumar L, Sahoo RK
    Azacitidine and Venetoclax in AML.
    N Engl J Med. 2020;383:2087.
    PubMed    


    October 2020
  16. HOELZER D
    Chemotherapy-free Treatment - A New Era in Acute Lymphoblastic Leukemia?
    N Engl J Med. 2020;383:1673-1674.
    PubMed    


  17. FOA R, Bassan R, Vitale A, Elia L, et al
    Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
    N Engl J Med. 2020;383:1613-1623.
    PubMed     Abstract available


  18. CAZZOLA M
    Myelodysplastic Syndromes.
    N Engl J Med. 2020;383:1358-1374.
    PubMed    


    August 2020
  19. PASRICHA TS, Abraczinskas D
    Gastrointestinal Myeloid Sarcoma.
    N Engl J Med. 2020;383:858.
    PubMed    


  20. SCHIFFER CA
    Promoting Apoptosis with Venetoclax - A Benefit for Older Patients with AML.
    N Engl J Med. 2020;383:677-679.
    PubMed    


  21. DINARDO CD, Jonas BA, Pullarkat V, Thirman MJ, et al
    Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
    N Engl J Med. 2020;383:617-629.
    PubMed     Abstract available


    July 2020
  22. AHN IE, Tian X, Wiestner A
    Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations.
    N Engl J Med. 2020;383:498-500.
    PubMed    


  23. BURGER JA
    Treatment of Chronic Lymphocytic Leukemia.
    N Engl J Med. 2020;383:460-473.
    PubMed    


    May 2020
  24. SEVESTRE J, Kopec L
    Disseminated Fusariosis.
    N Engl J Med. 2020;382:e64.
    PubMed    


    April 2020
  25. MAURO MJ, Hughes TP
    Asciminib in Relapsed Chronic Myeloid Leukemia. Reply.
    N Engl J Med. 2020;382:1379.
    PubMed    


  26. SAHIN I, Reagan JL
    Asciminib in Relapsed Chronic Myeloid Leukemia.
    N Engl J Med. 2020;382:1378-1379.
    PubMed    


    March 2020
  27. SYKES DB, Zhang EW, Karp Leaf RS, Nardi V, et al
    Case 10-2020: An 83-Year-Old Man with Pancytopenia and Acute Renal Failure.
    N Engl J Med. 2020;382:1258-1266.
    PubMed    


    February 2020
  28. LIU E, Marin D, Banerjee P, Macapinlac HA, et al
    Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
    N Engl J Med. 2020;382:545-553.
    PubMed     Abstract available


    December 2019
  29. HUGHES TP, Mauro MJ, Cortes JE, Minami H, et al
    Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
    N Engl J Med. 2019;381:2315-2326.
    PubMed     Abstract available


    November 2019
  30. CUMMINGS BM, Shailam R, Rosales AM, Huang MS, et al
    Case 37-2019: A 20-Month-Old Boy with Severe Anemia.
    N Engl J Med. 2019;381:2158-2167.
    PubMed    


    October 2019
  31. ALVERSON BK, Kilcoyne A, Friedmann AM, Sohani AR, et al
    Case 34-2019: A 16-Year-Old Boy with Jaundice.
    N Engl J Med. 2019;381:1763-1772.
    PubMed    


  32. PERL AE, Martinelli G, Cortes JE, Neubauer A, et al
    Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
    N Engl J Med. 2019;381:1728-1740.
    PubMed     Abstract available


    September 2019
  33. XU L, Wang J, Liu Y, Xie L, et al
    CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia.
    N Engl J Med. 2019 Sep 11. doi: 10.1056/NEJMoa1817426.
    PubMed     Abstract available


  34. JUNE CH
    Emerging Use of CRISPR Technology - Chasing the Elusive HIV Cure.
    N Engl J Med. 2019 Sep 11. doi: 10.1056/NEJMe1910754.
    PubMed    


    August 2019
  35. JAIN N, Gandhi V, Wierda W
    Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
    N Engl J Med. 2019;381:789.
    PubMed    


  36. KATER AP, Levin MD, Niemann CU
    Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    N Engl J Med. 2019;381:788-789.
    PubMed    


  37. SHANAFELT TD, Wang XV, Kay NE, Hanson CA, et al
    Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2019;381:432-443.
    PubMed     Abstract available


    July 2019
  38. CROMBIE JL, Venkateswaran R, Kim AS, Vaidya A, et al
    Bad to the Bone.
    N Engl J Med. 2019;381:e9.
    PubMed    


    June 2019
  39. ABBAS HA, Han X
    Cytoplasmic Blebs in T-Cell Prolymphocytic Leukemia.
    N Engl J Med. 2019;380:2360.
    PubMed    


  40. FISCHER K, Al-Sawaf O, Bahlo J, Fink AM, et al
    Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
    N Engl J Med. 2019;380:2225-2236.
    PubMed     Abstract available


    May 2019
  41. WIESTNER A
    Ibrutinib and Venetoclax - Doubling Down on CLL.
    N Engl J Med. 2019;380:2169-2171.
    PubMed    


  42. JAIN N, Keating M, Thompson P, Ferrajoli A, et al
    Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    N Engl J Med. 2019;380:2095-2103.
    PubMed     Abstract available


  43. REILLY BM
    Count Your Blessings.
    N Engl J Med. 2019;380:1690-1693.
    PubMed    


    April 2019
  44. WOYACH JA, Ruppert AS, Mandrekar SJ
    Ibrutinib Regimens in Older Patients with Untreated CLL. Reply.
    N Engl J Med. 2019;380:1680-1681.
    PubMed    


  45. MERCIER T, Janssens A, Maertens J
    Ibrutinib Regimens in Older Patients with Untreated CLL.
    N Engl J Med. 2019;380:1679-1681.
    PubMed    


  46. SENGAR M, Gogtay N, Jain H
    Ibrutinib Regimens in Older Patients with Untreated CLL.
    N Engl J Med. 2019;380:1679.
    PubMed    


  47. DIKER O
    Ibrutinib Regimens in Older Patients with Untreated CLL.
    N Engl J Med. 2019;380:1679.
    PubMed    


  48. PEMMARAJU N, Lane AA, Sweet KL, Stein AS, et al
    Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
    N Engl J Med. 2019;380:1628-1637.
    PubMed     Abstract available


  49. BERG DD, Kirshenbaum JM, Gay E, Miller AL, et al
    A Dangerous Detour.
    N Engl J Med. 2019;380:1360-1365.
    PubMed    


    March 2019
  50. CHRISTOPHER M, DiPersio JF, Ley TJ
    Immune Escape of AML Cells after Transplantation. Reply.
    N Engl J Med. 2019;380:1290.
    PubMed    


  51. GOODMAN AM, Kurzrock R
    Immune Escape of AML Cells after Transplantation.
    N Engl J Med. 2019;380:1289.
    PubMed    


  52. MARIN-HERNANDEZ D, Iniguez LP, Nixon DF
    Immune Escape of AML Cells after Transplantation.
    N Engl J Med. 2019;380:1289.
    PubMed    


  53. BERG DD, Kirshenbaum J, Gay E, Vaidya A, et al
    A Dangerous Detour.
    N Engl J Med. 2019;380:e18.
    PubMed    


    February 2019
  54. SOUMERAI JD, Tajmir SH, Hirsch MS, Massoth LR, et al
    Case 7-2019: A 73-Year-Old Woman with Swelling of the Right Groin and Fever.
    N Engl J Med. 2019;380:859-868.
    PubMed    


    January 2019
  55. YAMAUCHI J, Yamano Y, Yuzawa K
    Risk of Human T-Cell Leukemia Virus Type 1 Infection in Kidney Transplantation.
    N Engl J Med. 2019;380:296-298.
    PubMed    


    December 2018
  56. LOREN AW
    Harder to Treat Than Leukemia - Opioid Use Disorder in Survivors of Cancer.
    N Engl J Med. 2018;379:2485-2487.
    PubMed    


  57. WOYACH JA, Ruppert AS, Heerema NA, Zhao W, et al
    Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
    N Engl J Med. 2018;379:2517-2528.
    PubMed     Abstract available


  58. CHRISTOPHER MJ, Petti AA, Rettig MP, Miller CA, et al
    Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.
    N Engl J Med. 2018;379:2330-2341.
    PubMed     Abstract available


    November 2018
  59. ULRICH BC
    Clonal Hematopoiesis Leading to AITL and NPM1-Mutated AML.
    N Engl J Med. 2018;379:2184.
    PubMed    


  60. TIACCI E, Falini B
    Clonal Hematopoiesis Leading to AITL and NPM1-Mutated AML.
    N Engl J Med. 2018;379:2184-2185.
    PubMed    


  61. EBERT BL, Kronke J
    Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia.
    N Engl J Med. 2018;379:1873-1874.
    PubMed    


    September 2018

  62. Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
    N Engl J Med. 2018;379:1186.
    PubMed    


  63. YUN S, Vincelette ND
    Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
    N Engl J Med. 2018;379:1186.
    PubMed    


  64. SAHIN I
    Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
    N Engl J Med. 2018;379:1186.
    PubMed    


  65. IYASERE CA, Takvorian RW, Simeone FJ, Siegele BJ, et al
    Case 28-2018: A 39-Year-Old Man with Epistaxis, Pain and Erythema of the Forearm, and Pancytopenia.
    N Engl J Med. 2018;379:1072-1081.
    PubMed    


  66. DUNCAVAGE EJ, Jacoby MA, Chang GS, Miller CA, et al
    Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
    N Engl J Med. 2018;379:1028-1041.
    PubMed     Abstract available


  67. TIACCI E, Venanzi A, Ascani S, Marra A, et al
    High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML.
    N Engl J Med. 2018;379:981-984.
    PubMed    


    August 2018
  68. KATAOKA K, Ogawa S
    PD-1 Inhibitor Therapy in Adult T-Cell Leukemia-Lymphoma.
    N Engl J Med. 2018;379:696.
    PubMed    


  69. ISHITSUKA K, Utsunomiya A, Ishida T
    PD-1 Inhibitor Therapy in Adult T-Cell Leukemia-Lymphoma.
    N Engl J Med. 2018;379:695.
    PubMed    



  70. PD-1 Inhibitor Therapy in Adult T-Cell Leukemia-Lymphoma.
    N Engl J Med. 2018;379:695-697.
    PubMed    


    July 2018
  71. KARLSSON S
    Tipping Clonal Hematopoiesis into Transformation.
    N Engl J Med. 2018;379:295-296.
    PubMed    


    June 2018
  72. MAUVIEUX L, Miguet L, Fornecker L
    Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:2442-3.
    PubMed    


  73. ULRICH BC
    Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:2442.
    PubMed    



  74. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:2442-2443.
    PubMed    


  75. DINARDO CD, Stein EM, de Botton S, Roboz GJ, et al
    Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    N Engl J Med. 2018;378:2386-2398.
    PubMed     Abstract available


    May 2018
  76. COPUR MS, Gauchan D, Crockett D
    Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2018;378:2142-3.
    PubMed    


  77. FERHANOGLU B, Ozturk E, Ozbalak M
    Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2018;378:2141-2.
    PubMed    



  78. Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2018;378:2141-2144.
    PubMed    


  79. RATNER L, Waldmann TA, Janakiram M, Brammer JE, et al
    Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy.
    N Engl J Med. 2018;378:1947-1948.
    PubMed    


    April 2018
  80. KORONES DN
    The Long Ride Home.
    N Engl J Med. 2018;378:1569-1571.
    PubMed    



  81. More on Ofatumumab for TTP.
    N Engl J Med. 2018;378:1364-1365.
    PubMed    


    March 2018
  82. JONGEN-LAVRENCIC M, Grob T, Hanekamp D, Kavelaars FG, et al
    Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:1189-1199.
    PubMed     Abstract available


  83. STEENSMA DP, Ebert BL
    Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:1244-1245.
    PubMed    


  84. SEYMOUR JF, Kipps TJ, Eichhorst B, Hillmen P, et al
    Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    N Engl J Med. 2018;378:1107-1120.
    PubMed     Abstract available


    February 2018
  85. EL-JAWAHRI AR, Schaefer PW, El Khoury JB, Martinez-Lage M, et al
    Case 5-2018: A 63-Year-Old Man with Confusion after Stem-Cell Transplantation.
    N Engl J Med. 2018;378:659-669.
    PubMed    


  86. PARK JH, Riviere I, Gonen M, Wang X, et al
    Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
    N Engl J Med. 2018;378:449-459.
    PubMed     Abstract available


  87. MAUDE SL, Laetsch TW, Buechner J, Rives S, et al
    Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
    N Engl J Med. 2018;378:439-448.
    PubMed     Abstract available


    January 2018
  88. HIBBERT KA, Shepard JO, Lane RJ, Azar MM, et al
    Case 1-2018. A 39-Year-Old Woman with Rapidly Progressive Respiratory Failure.
    N Engl J Med. 2018;378:182-190.
    PubMed    


    December 2017
  89. KORTE AKM, Vos JM
    Ecthyma Gangrenosum.
    N Engl J Med. 2017;377:e32.
    PubMed    


    November 2017
  90. SAHOO RK, Kumar L
    Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
    N Engl J Med. 2017;377:1901-2.
    PubMed    


  91. ESKAZAN AE
    Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
    N Engl J Med. 2017;377:1901.
    PubMed    



  92. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
    N Engl J Med. 2017;377:1902.
    PubMed    


    October 2017
  93. ROSENBAUM L
    Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy.
    N Engl J Med. 2017;377:1313-1315.
    PubMed    


    August 2017
  94. BRAUN R, Holler E
    Acute Ocular Graft-versus-Host Disease.
    N Engl J Med. 2017;377:676.
    PubMed    


    June 2017
  95. STONE RM, Mandrekar SJ, Sanford BL, Laumann K, et al
    Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
    N Engl J Med. 2017 Jun 23. doi: 10.1056/NEJMoa1614359.
    PubMed     Abstract available



  96. Blinatumomab for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2017;376:e49.
    PubMed    



  97. Blinatumomab for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2017;376:e49.
    PubMed    


  98. SPIVAK JL
    Myeloproliferative Neoplasms.
    N Engl J Med. 2017;376:2168-2181.
    PubMed    


    May 2017
  99. GORDON SW, Krystal GW
    Auer Rods.
    N Engl J Med. 2017;376:2065.
    PubMed    


    April 2017
  100. GREMBECKA J, Cierpicki T
    Stabilizing the Mixed Lineage Leukemia Protein.
    N Engl J Med. 2017;376:1688-1689.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: